Netbiotix raises €7,5M to bring its lead candidate for inflammatory bowel disease into clinical trials.
The treatment uses a bacterium found in the gut to prevent and dampen inflammation.
Netbiotix, a Paris based Company, develops treatments for inflammatory bowel disease (IBD) that consist of a single microbial strain that interacts with cells in the intestine. The Series A round was led by Auriga Partners, who were joined by other investors, including Biocodex, a multinational pharmaceutical company focused on gastroenterology and microbiome research.
Netbiotix’s lead treatment uses a bacterium, called Faecalibacterium prausnitzii, which according to the company is the most abundant bacteria in the whole human gut microbiome. The bacterium stimulates an anti-inflammatory immune response in the gut by activating certain cell signalling pathways in intestinal cells. This effect could potentially improve the lives of patients with IBD.